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Abstract
Beam-shaping assemblies have been designed to moderate high energy neutrons from the fusion
reactions
2
H(d; n)
3
He (DD) and
3
H(d;n)
4
He (DT) for use in Boron Neutron Capture Therapy. The
low yield of DD is an obstacle for the treatment of Glioblastoma Multiforme. Our analysis shows that
the high-energy neutrons from DT can be moderated to epithermal energy range without reducing
the neutron ux to a negligible level. With the optimal beam-shaping assembly design for DT, a 1 A
deuteron beam with energy of 120 keV leads to a treatment time of 50 minutes. The dose near the
center of the brain obtained with this conguration is about 50% higher than the dose from a typical
spectrum produced by the Brookhaven Medical Research Reactor (BMRR), and is comparable to the
dose obtained by other accelerator-produced neutron beams.
1 INTRODUCTION
The main goal in this study is to identify some alternative accelerator-based reactions that could result in
a simple and inexpensive accelerator and target system while satisfying all of the requirements for boron
neutron capture therapy (BNCT).
The need for epithermal neutron beams with energy distribution peaking around 10 keV [1, 2]
led dierent groups to investigate reactor- and accelerator-based neutron sources. Reactions such as
7
Li(p; n),
9
Be(p; n) and
9
Be(d; n) are currently being investigated as accelerator-based neutron sources
for BNCT because the energy of neutrons is of the order of hundreds of keV [2, 3, 4]. The drawback of
these reactions is the high energy of the protons and deuterons required, which varies usually between
2.3 and 4.0 MeV depending on the reaction, requiring a large accelerator and treatment facility.
To the best of authors knowledge, the reactions
2
H(d; n)
3
He (DD) and
3
H(d; n)
4
He (DT) have
not been investigated so far for BNCT, because of the high energy of the neutrons produced, 2.43 and 14.1
MeV respectively. Provided these neutrons can be moderated to therapeutically useful regions without
large losses, the high neutron yields for relatively low deuteron beam energy (100-200 keV) is a denite
advantage over other accelerator-based neutron sources. A 120 keV deuteron beam yields approximately
3:710
11
n=sec=A and 10
14
n=sec=A for DD and DT respectively [5]. This paper investigates the feasibility
of generating neutrons for BNCT using the DD and DT reactions. It focuses on two points: designing a
moderator to decrease neutron energies to epithermal regions and determining the dose distribution in a
head phantom. Monte-Carlo codes are used for both tasks.
2 NEUTRON BEAM-SHAPING ASSEMBLY (BSA)
In order to obtain a therapeutically useful epithermal neutron beam, the BSA needs to be optimized.
The neutron transport through the BSA is simulated using the Monte-Carlo code MCNP [6]. After
moderation, a second Monte-Carlo code BNCT RTPE [7] is used to calculate the dose distribution in a
head phantom.
The neutron source is characterized as follows. Monoenergetic neutrons are emitted isotropically
and uniformly from a 5 cm-diameter spotsize on a 40 cm-diameter target. Source neutrons enter a
cylindrical BSA with a monoenergetic energy distribution. They travel through the cylinder composed
of several layers of dierent materials until they reach the other side where the patient is located.
An accepted gure-of-merit used to measure the neutron beam quality is the dose equivalent to
the tumor at the centerline of the brain, and it is based on biological criteria. The tumor dose at a
Figure 1: Beam-shaping assembly (BSA).
depth of 8 cm is used as a gure-of-merit in our study. This dose is limited by Brookhaven National
Laboratory's (BNL) clinical trial protocol [8] which suggests that the local equivalent dose to the healthy
tissues must not exceed 12.5 Gy. The treatment time will thus be limited by this value.
For the dose computation with BNCT RTPE [7], concentrations of 13g=g of
10
B in healthy
tissues and 45:5g=g of
10
B in tumor are used. The individual dose components (boron dose, gamma
dose, nitro-dose and fast dose) are combined to yield estimates of total doses per neutron to healthy
tissue and tumor, using the following equation:
D
total
= CF D
B
+RBE
N
D
N
+RBE
r
D
r
+RBE

D

where the following assumptions are made: the normal tissue and tumor compound factors CF
are 1.3 and 3.8, respectively; proton-recoil reactions RBE
r
: 3.2; nitrogen capture reaction RBE
N
: 3.2;
RBE

: 1.0. The
10
B concentrations, compound factors and RBE factors were taken from values used in
BNL's protocol [8].
2.1 Optimal BSA and dose distribution for DD
The optimal combination of materials that we came up with for DD was 30 cm of
7
LiF and 18 cm of
40%Al/60%AlF
3
. The BSA is 25 cm in diameter and surrounded by a thin (0.5 mm) layer of
6
LiF and
a thick 30 cm Al
2
O
3
reector. A detailed description of the geometry can be found in Ref. [9]. The
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Figure 2: (a) Neutron energy distribution after moderation and (b) total dose to the healthy tissues with
the dierent dose components in the head phantom.
neutron spectrum after moderation and the equivalent doses to the healthy tissues (with its components)
are shown in Fig. 2. The equivalent tumor dose to the desired depth of 8 cm with this moderation is
18 Gy-Eq. The equivalent skin dose is 8.9 Gy-Eq. Accounting for the neutron yield of DD | which
is 8:5  10
9
n=sec=mA for a 400 keV beam [10] | this moderation would lead to a treatment time of
840 hours for a 5 mA deuteron beam. Even with a 1 A deuteron beam, the treatment time would be
more than 4 hours. This unacceptably large treatment time could potentially be reduced by using several
beams, by increasing the beam intensity, or by improving the beam shaping assembly.
2.2 Optimal BSA and dose distribution for DT
A few simulations for dierent combinations of materials showed that all neutrons above 1 MeV contribute
not only to the fast dose at the surface of the brain, but also to the fast dose throughout the head, including
the point of maximum tissue dose which limits the treatment time. The BSA optimization emphasis was
thus on decreasing the high energy neutron ux to a level as low as possible.
The best BSA design we came up with was composed of thick layers of bismuth, iron, 40%Al/60%AlF
3
,
and of thin layers of
6
LiF and lead. The BSA is surrounded by a 20 cm thick lead reector. The large
cross-sections of bismuth and lead for (n,2n) reactions are used benecially to compensate for the neutron
losses by leakage and absorption during the moderation. Iron is used to reduce the fast neutron energies
from 14 MeV to around 1 MeV. The mixture 40%Al/60%AlF
3
is interesting in the sense that the elastic
scattering resonances of aluminum supplement exactly the ones of uorine from 27 keV up to the high
energy tail, except for a narrow energy range around 70 keV. This resonance structure will preferentially
reduce the number of neutrons above 27 keV. Lithium uoride and lead are nally used to reduce the
thermal neutron ux and to decrease the photon ux respectively at the end of the moderator.
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Figure 3: (a) Neutron energy distribution after moderation and (b) total dose to the healthy tissues with
the dierent dose components in the head phantom.
The neutron spectrum after moderation and the components of the doses to the healthy tissues
are shown in Fig. 3. With this moderation, the equivalent tumor dose in the head phantom at 8 cm
depth is 21.9 Gy-Eq and the equivalent dose to the skin is 9.6 Gy-Eq. With a 120 keV deuteron beam,
a 1 A deuteron beam intensity would lead to a treatment time of 50 minutes.
2.3 Summary and comparison with other neutron sources
Table 1 summarizes the main characteristics of the tumor dose distribution for DD, DT and other neutron
sources proposed or used for BNCT. The optimized spectrum from the DT neutron source produces about
50% higher dose near the center of the brain than the currently used reactor spectrum at BMRR.
3 CONCLUSIONS
Two fusion reactions (DD and DT) have been studied as possible neutron sources for BNCT. The low
neutron yield of the DD reaction is an obstacle for its use in this particular therapy. Neutrons from the
Neutron source
3
H(d; n)
4
He
2
H(d; n)
3
He
7
Li(p; n)
7
Be
7
Li(p; n)
7
Be BMRR
Moderator Bi=Fe
7
LiF
7
LiF Al=AlF
3
(Al
2
O
3
)
Al=AlF
3
Al=AlF
3
[2] [2] [11]
Proton energy [MeV] 0.12 0.4 2.3 2.4 -
Proton current [mA] 1000 5000 20 20 (3 MW)
Treatment time [min] 50 50 40 54 39
Equ. tumor dose (max) [Gy-Eq] 64.8 60.1 64.3 65.1 61.6
Equ. tumor dose (5 cm) [Gy-Eq] 51.8 42.9 50.5 51.4 38.6
Equ. tumor dose (8 cm) [Gy-Eq] 21.9 18.0 21.4 22.3 14.5
Advantage depth [cm] 9.5 9.0 9.5 9.5 8.4
Table 1: Comparison of treatment characteristics for dierent neutron sources.
DT reaction could be moderated to around 10 keV without reducing the neutron ux to a negligible
level. An equivalent tumor dose of 21.9 Gy-Eq could be achieved at a depth of 8 cm in the head pantom,
which is about 50% higher than doses obtained by a neutron beam currently used at BMRR for clinical
trials. For a treatment time of 50 minutes, the deuteron beam requirements are 120 keV and 1 A. Taking
advantage of the small sizes of the ion sources and accelerators, several beams could easily be used in
parallel and treatment times could be reduced to a fraction of an hour.
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